Mesalamine Granules 1500 mg Once Daily for 12 Weeks Provides Adequate Relief of IBS Symptoms in Irritable Bowel Syndrome with Diarrhea: Results from a Phase 2 Trial

Aron, Jeffrey; Lin, Mimi; Yu, Jie; Paterson, Craig; Bortey, Enoch; Forbes, William

doi:10.14309/00000434-201210001-01749

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We identified three RCTs of 5-ASAs in IBS (281)(282)(283), all of which used mesalamine, and contained 464 patients. Two RCTs were at low risk of bias (281,282).…”

Section: Quality Of Evidence: Lowmentioning

confidence: 99%

See 1 more Smart Citation

American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome

Ford

Martin

Chey

et al. 2018

American Journal of Gastroenterology

286

396

View full text Add to dashboard Cite

IntroductionIrritable bowel syndrome (IBS) is the most prevalent of the functional gastrointestinal disorders (FGIDs). Current estimates are that IBS affects up to 10-12% of adults in North America (1,2). Although it can affect all individuals regardless of age, creed, or gender, IBS is more common among women and is most commonly diagnosed in younger individuals (< age 50) (2, 3). IBS is characterized by recurrent abdominal pain and altered bowel habits; bloating and distention frequently coexist. The diagnosis of IBS is made by taking a careful history, eliciting key symptoms, as well as performing a physical examination and limited diagnostic testing (4-6). IBS is categorized into four main subtypes based on the predominant bowel habit: IBS with constipation (IBC-C); IBS with diarrhea (IBS-D); IBS with mixed symptomology (IBS-M); and unclassified IBS (5).IBS imposes a significant burden to the health care system and to individuals.Direct medical costs attributed to IBS in the US, excluding prescription and over-thecounter medicines, were estimated at $1.5-$10 billion per year in 2005 (7). Patients with IBS enrolled in a large Health Maintenance Organization (HMO) had significantly more outpatient visits and incurred nearly 50% more in total costs than individuals without IBS (8). A retrospective case-control study from another large HMO reported that patients with IBS had significantly more diagnostic tests, imaging, and surgery compared with patients without a diagnosis of IBS (9). Significant variations in care across the United States related to the diagnosis and treatment of IBS also play a role in excessive health care costs (10). The burden of IBS on individuals can be measured in a number of ways. Studies have demonstrated consistently that IBS impairs work-related activities (e.g., lost work time, reduced productivity while at work) and also reduces quality of life (11,12). The development Ford et al.Page 3 of 91 of effective and efficient treatment strategies for IBS assumes considerable importance, therefore, not just for the individual sufferer, but for society at large.Given the clinical heterogeneity that is a hallmark of the disorder and the absence of a single effective therapy for all sufferers, available therapies tend to focus on predominant symptomatology at presentation (i.e., altered bowel habits, abdominal pain, or bloating) (4-6). Based on their purported mode of action, many pharmacological therapies for IBS developed in recent decades have been directed towards those with a particular bowel habit, whether diarrhea or constipation.However, treating IBS patients can be difficult as no validated treatment algorithm exists, not all patients respond to treatment, and patients with similar symptoms frequently respond to the same treatment differently. Fortunately, a variety of novel therapeutic strategies are being explored and new compounds have appeared since the last iteration of the ACG monograph on IBS (4). The goal of this document, therefore, is to provide an updated, evidence-based d...

show abstract

“…We identified three RCTs of 5-ASAs in IBS (281)(282)(283), all of which used mesalamine, and contained 464 patients. Two RCTs were at low risk of bias (281,282).…”

Section: Quality Of Evidence: Lowmentioning

confidence: 99%

“…One trial used a dose of either 750 mg or 1.5g mesalamine o.d. (283), one trial used a dose of 2g b.i.d. (282), and the third used 800mg t.i.d.…”

Section: Quality Of Evidence: Lowmentioning

confidence: 99%

American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome

Ford

Martin

Chey

et al. 2018

American Journal of Gastroenterology

286

396

View full text Add to dashboard Cite

show abstract

Systematic Review and Meta-analysis: Efficacy of Mesalamine in Irritable Bowel Syndrome

Goodoory

Tuteja

Black

et al. 2024

Clinical Gastroenterology and Hepatology

View full text Add to dashboard Cite

El síndrome del intestino irritable, ¿ya no debe ser considerado un trastorno funcional?

Sebastián-Domingo¹

2013

Medicina Clínica

View full text Add to dashboard Cite

Mesalamine Granules 1500 mg Once Daily for 12 Weeks Provides Adequate Relief of IBS Symptoms in Irritable Bowel Syndrome with Diarrhea: Results from a Phase 2 Trial

Cited by 4 publications

References 0 publications

American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome

American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome

Systematic Review and Meta-analysis: Efficacy of Mesalamine in Irritable Bowel Syndrome

El síndrome del intestino irritable, ¿ya no debe ser considerado un trastorno funcional?

Contact Info

Product

Resources

About